人乳头瘤病毒预防性疫苗：既定的成功，新的方法。
Papillomavirus prophylactic vaccines: established successes, new approaches.
机构信息
Division of Pathological Sciences, Institute of Comparative Medicine, Garscube Campus, University of Glasgow, Glasgow G61 1QH, United Kingdom.
出版信息
J Virol. 2010 Feb;84(3):1214-20. doi: 10.1128/JVI.01927-09. Epub 2009 Nov 11.
Abstract
Vaccines against the human papillomaviruses (HPVs) most frequently associated with cancer of the cervix are now available. These prophylactic vaccines, based on virus-like particles (VLPs), are extremely effective, providing protection from infection in almost 100% of cases. However, the vaccines present some limitations: they are effective primarily against the HPV type present in the vaccine, are expensive to produce, and need a cold chain. Vaccines based on the minor capsid protein L2 have been very successful in animal models and have been shown to provide a good level of protection against different papillomavirus types. The potential of L2-based vaccines to protect against many types of HPVs is discussed.
摘要
目前已有针对与宫颈癌最相关的人类乳头瘤病毒（HPV）的疫苗。这些基于病毒样颗粒（VLPs）的预防性疫苗非常有效，几乎能 100%预防感染。然而，这些疫苗存在一些局限性：它们主要针对疫苗中存在的 HPV 类型有效，生产成本高，并且需要冷链。基于次要衣壳蛋白 L2 的疫苗在动物模型中非常成功，并已证明能提供针对不同乳头瘤病毒类型的良好保护水平。讨论了基于 L2 的疫苗预防多种 HPV 的潜力。
相似文献
1
Papillomavirus prophylactic vaccines: established successes, new approaches.
J Virol. 2010 Feb;84(3):1214-20. doi: 10.1128/JVI.01927-09. Epub 2009 Nov 11.
2
Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
J Virol. 2016 Jun 24;90(14):6314-25. doi: 10.1128/JVI.00449-16. Print 2016 Jul 15.
3
Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
J Virol. 2018 Jan 30;92(4). doi: 10.1128/JVI.01930-17. Print 2018 Feb 15.
4
A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9.
Antiviral Res. 2017 Nov;147:116-123. doi: 10.1016/j.antiviral.2017.09.012. Epub 2017 Sep 20.
5
Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?
Viruses. 2019 Dec 23;12(1):18. doi: 10.3390/v12010018.
6
Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
J Natl Cancer Inst. 2009 Jun 3;101(11):782-92. doi: 10.1093/jnci/djp106. Epub 2009 May 26.
7
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24.
8
Strategies for Developing Oral Vaccines for Human Papillomavirus (HPV) Induced Cancer using Nanoparticle mediated Delivery System.
J Pharm Pharm Sci. 2015;18(2):220-34. doi: 10.18433/j3rs3v.
9
Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.
Antiviral Res. 2019 Jun;166:56-65. doi: 10.1016/j.antiviral.2019.03.012. Epub 2019 Mar 26.
10
Developments in L2-based human papillomavirus (HPV) vaccines.
Virus Res. 2017 Mar 2;231:166-175. doi: 10.1016/j.virusres.2016.11.020. Epub 2016 Nov 23.
引用本文的文献
1
The contribution of bovines to human health against viral infections.
Environ Sci Pollut Res Int. 2021 Sep;28(34):46999-47023. doi: 10.1007/s11356-021-14941-z. Epub 2021 Jul 16.
2
Novel Production of Bovine Papillomavirus Pseudovirions in Tobacco Plants.
Pathogens. 2020 Nov 28;9(12):996. doi: 10.3390/pathogens9120996.
3
Identification of bovine papillomavirus type 1 and 2 from bovine anogenital fibropapillomas.
J Vet Med Sci. 2019 Jul 19;81(7):1000-1005. doi: 10.1292/jvms.19-0017. Epub 2019 Jun 3.
4
Viral Oncology: Molecular Biology and Pathogenesis.
J Clin Med. 2017 Nov 29;6(12):111. doi: 10.3390/jcm6120111.
5
HPV entry into cells.
Mutat Res Rev Mutat Res. 2017 Apr-Jun;772:13-22. doi: 10.1016/j.mrrev.2016.09.004. Epub 2016 Sep 23.
6
Intranasal immunization of pigs with porcine reproductive and respiratory syndrome virus-like particles plus 2', 3'-cGAMP VacciGrade™ adjuvant exacerbates viremia after virus challenge.
Virol J. 2017 Apr 12;14(1):76. doi: 10.1186/s12985-017-0746-0.
7
Progress and prospects for L2-based human papillomavirus vaccines.
Expert Rev Vaccines. 2016 Jul;15(7):853-62. doi: 10.1586/14760584.2016.1157479. Epub 2016 Mar 10.
8
Tracking vaginal, anal and oral infection in a mouse papillomavirus infection model.
J Gen Virol. 2015 Dec;96(12):3554-3565. doi: 10.1099/jgv.0.000295.
9
Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus.
J Clin Med. 2015 Apr 3;4(4):614-33. doi: 10.3390/jcm4040614.
10
Development of an IP-Free Biotechnology Platform for Constitutive Production of HPV16 L1 Capsid Protein Using the Pichia pastoris PGK1 Promoter.
Biomed Res Int. 2015;2015:594120. doi: 10.1155/2015/594120. Epub 2015 May 18.
本文引用的文献
1
How much will it hurt? HPV vaccine side effects and influence on completion of the three-dose regimen.
Vaccine. 2009 Nov 16;27(49):6840-4. doi: 10.1016/j.vaccine.2009.09.016. Epub 2009 Sep 16.
2
Loss of epidermal Langerhans cells occurs in human papillomavirus alpha, gamma, and mu but not beta genus infections.
J Invest Dermatol. 2010 Feb;130(2):472-80. doi: 10.1038/jid.2009.266. Epub 2009 Sep 17.
3
Bovine papillomavirus type 1 (BPV1) and BPV2 are closely related serotypes.
Virology. 2009 Oct 10;393(1):1-6. doi: 10.1016/j.virol.2009.07.036. Epub 2009 Sep 3.
4
Reversal of papilloma growth in rabbits therapeutically vaccinated against E6 with naked DNA and/or vesicular stomatitis virus vectors.
Vaccine. 2010 Dec 6;28(52):8345-51. doi: 10.1016/j.vaccine.2009.04.082. Epub 2009 Jul 15.
5
Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
J Natl Cancer Inst. 2009 Jun 3;101(11):782-92. doi: 10.1093/jnci/djp106. Epub 2009 May 26.
6
Human papillomavirus research: do we still need animal models?
Int J Cancer. 2009 Aug 1;125(3):739-40. doi: 10.1002/ijc.24430.
7
Papillomavirus and disease in humans and animals.
Vet Comp Oncol. 2003 Mar;1(1):3-14. doi: 10.1046/j.1476-5829.2003.00001.x.
8
Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20 -- 38) peptide displayed on bacterial thioredoxin.
Vaccine. 2009 Mar 18;27(13):1949-56. doi: 10.1016/j.vaccine.2009.01.102. Epub 2009 Jan 31.
9
Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity.
Vaccine. 2009 Feb 11;27(7):1040-9. doi: 10.1016/j.vaccine.2008.11.099. Epub 2008 Dec 16.
10
Papillomavirus E6 proteins.
Virology. 2009 Feb 20;384(2):324-34. doi: 10.1016/j.virol.2008.11.017. Epub 2008 Dec 10.
Zotero 插件